Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1818 1
1819 1
1824 1
1826 1
1827 1
1828 7
1829 7
1830 1
1833 1
1834 1
1838 1
1839 2
1844 1
1845 1
1846 1
1849 3
1851 1
1855 2
1856 1
1903 1
1911 1
1930 1
1947 1
1960 1
1965 2
1966 1
1967 1
1968 1
1970 1
1973 1
1976 2
1978 1
1979 2
1980 5
1981 2
1982 6
1983 4
1984 6
1985 3
1986 10
1987 4
1988 5
1989 2
1990 3
1991 3
1992 3
1993 4
1994 1
1995 6
1996 4
1997 6
1998 5
1999 7
2000 4
2001 3
2002 5
2003 5
2004 3
2005 2
2006 6
2007 4
2008 8
2009 10
2010 12
2011 13
2012 14
2013 13
2014 13
2015 16
2016 9
2017 6
2018 5
2019 9
2020 6
2021 10
2022 12
2023 13
2024 10
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Results by year

Filters applied: . Clear all
Page 1
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. McMurray JJ, et al. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. N Engl J Med. 2014. PMID: 25176015 Free article. Clinical Trial.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Cannon CP, et al. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. N Engl J Med. 2015. PMID: 26039521 Free article. Clinical Trial.
Subclinical atrial fibrillation and the risk of stroke.
Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Healey JS, et al. N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575. N Engl J Med. 2012. PMID: 22236222 Free article. Clinical Trial.
[Introduction].
Groupe d'étude MACVIA-LR. Groupe d'étude MACVIA-LR. Presse Med. 2015 Nov;44 Suppl 1:S1-5. doi: 10.1016/j.lpm.2015.07.014. Epub 2015 Oct 18. Presse Med. 2015. PMID: 26476754 French. No abstract available.
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Robinson JG, et al. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030. JAMA. 2014. PMID: 24825642 Clinical Trial.
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. McMurray JJ, et al. Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5. Eur J Heart Fail. 2013. PMID: 23563576 Free PMC article. Clinical Trial.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
Cardiovascular adverse effects of anti-inflammatory drugs.
Roubille C, Martel-Pelletier J, Davy JM, Haraoui B, Pelletier JP. Roubille C, et al. Among authors: davy jm. Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):55-67. doi: 10.2174/1871523011312010008. Antiinflamm Antiallergy Agents Med Chem. 2013. PMID: 23286294 Review.
331 results